Barcelona researchers reported memory-test gains in a small eye-tracking study. Read how risk-dependent blood results and evidence gaps limit the claims.
On October 19, 2026, the University of Barcelona reported early results from an eye-tracking cognitive-training study involving 29 people with mild cognitive impairment (MCI). The university said memory-test scores improved after eight weeks of game use, while changes in Alzheimer’s-related blood proteins differed between participant risk groups.
The university’s account describes a game that asks users to follow visual targets while ignoring distractions. Participants used it for 10 minutes a day, five days a week. According to the university, the task is intended to stimulate attention and eye movements.
The system also uses eye tracking to analyze eye movements and pupil responses. This gives the project two connected parts: a training activity and a way to examine how the eyes respond. The university describes a functional prototype whose analysis system is still being refined.
The participants had an average age of 77 and had already been diagnosed with MCI. Researchers divided them into groups according to their risk of progressing to Alzheimer’s dementia. Both groups used the game during the eight-week study.
The University of Barcelona reported the following pattern:
These findings need to remain separate when describing the results. The reported memory-test improvements occurred across both groups. The reported reductions in the two blood proteins did not.
A Springer Nature listing dates the related GeroScience article to August 12, 2026. Its title describes disease-stage-dependent effects on blood tau, cognition and eye-movement measures in patients with MCI. The October university report brought those findings to a wider audience.
One useful feature of the report is that it presents more than a memory score alone. It describes attention-based training alongside eye measurements and blood findings. That combination provides several outcomes to investigate, rather than a single result that settles whether the intervention works.
For someone with MCI, the immediate value is a more informed conversation about digital cognitive training. The report gives patients and clinicians a specific research approach to discuss. It does not establish a new treatment plan.
A useful conversation would distinguish the purpose of each part of the project. The game is the training activity. Eye tracking is used to analyze responses. Memory tests and blood measurements are separate outcomes used to assess what changed during the study.
Keeping those roles clear helps avoid treating every feature as a proven benefit. A tool that records eye movements is not automatically an established diagnostic test. A training task that participants can complete is not automatically an effective treatment.
The reported schedule also needs careful handling. Ten minutes daily on five days each week describes what these participants did. It is not a clinically established prescription for other people or for other digital products.
For readers weighing brain-training claims, the broader issue is how cognitive-training evidence is assessed. The relevant question is not just whether an activity sounds mentally demanding. It is whether research supports the particular benefit being advertised.
Personal cognitive concerns belong with a qualified clinician rather than with a game or eye-tracking tool alone. A discussion of memory changes and potentially modifiable risks is separate from deciding whether one experimental training approach has enough evidence behind it.
The central boundary is straightforward: this study does not establish Alzheimer’s prevention or slower disease progression. It involved people with MCI, so it also does not establish that the game prevents memory decline in healthy older adults.
The university suggests that the differing blood-protein results may indicate greater usefulness in earlier disease stages. That is an interpretation to test. The risk groups should not be turned into a rule for choosing who should use the game.
The higher-risk group’s pTau-181 increase belongs in any balanced account of the findings. Reporting only the lower-risk reductions would give readers an incomplete picture. The same applies to describing the intervention as lowering Alzheimer’s-related blood proteins without naming the group in which those reductions occurred.
University researcher Hans Super called the findings “a promising first step.” He also said the approach is not a cure and requires further research. That framing fits an early investigation better than a prevention claim.
Several unanswered questions determine how much weight the findings can carry:
These gaps matter because a reported improvement and a dependable everyday benefit are different claims. Better performance on a test does not, by itself, show that someone will manage daily responsibilities more easily. That connection needs to be measured rather than assumed.
The university also says the team is working toward clinical validation. The prototype should therefore not be presented as a clinically validated diagnostic or routine preventive intervention.
A practical reading rule follows from these limits: match the claim to the outcome actually reported. Here, the supported description is memory-test improvement during a small study, alongside blood-protein changes that differed by baseline risk. Stronger claims need stronger evidence.
The long-term value of this project lies in the questions it brings together. The University of Barcelona team is examining a training task alongside eye responses and blood measures. That creates a research direction in which different kinds of change can be studied together without assuming they will always agree.
For cognitive health, that distinction matters. A useful intervention must earn confidence through evidence about meaningful outcomes, not simply through an appealing activity or an encouraging headline. The next scientific task is to establish which reported changes are dependable and what they mean for people’s lives.
This study deserves attention as an early investigation. Its contribution is a set of findings to test more rigorously, rather than a reason to reorganize personal brain-health care around a game.
Eye-tracking games bring a simple activity into a research setting where interpreting the results is less simple. FitBrainLab helps adults 60+ assess early health claims through accessible explanations of memory and cognitive aging, so a promising headline is easier to place in context. Its research-led approach separates evidence from expectation without using fear or making medical promises.
Follow FitBrainLab for research-led insights on memory, focus, brain aging, nutrition and mental fitness after 60. Stay connected for new articles, practical guidance and ideas for a sharper, more engaged life.



Build habits that support memory, focus and a curious, connected life.
Read the Blog